Loading...
NPI 1316206220 · San Francisco, CA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Invitae Corporation is a clinical medical laboratory provider located in San Francisco, California. This profile covers 8 Medicare and 118 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Invitae Corporation |
| Address | 1400 16th St |
| City | San Francisco |
| State | CA |
| ZIP | 94103 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | May 11, 2012 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $136.7M |
| Medicare | $71.4M |
INVITAE CORPORATION is operating as a high-volume clinical molecular diagnostics lab focused on broad molecular pathology services, as reflected by Medicare's top revenue code 81479 and multiple tiered molecular pathology codes (81321, 81404, 81405, 81406). The prominence of 81479 on Medicare and a long list of genetic sequencing and panel codes indicates the organization primarily provides advanced genetic testing and sequencing rather than routine clinical laboratory testing. This billing mix is consistent with a specialized genetics testing service line that handles complex molecular diagnostics at scale.
Revenue concentration on Medicare is extremely high: the precomputed top 3 Medicare codes account for 99.8% of this provider's total Medicare revenue, with 81479 alone representing $68.1M (95.5% of Medicare revenue). That concentration implies Medicare revenue is overwhelmingly driven by a single high-level molecular pathology code, making Medicare performance and policy changes tied to that code particularly material to overall Medicare revenue. Analysts should monitor reimbursement or coding policy shifts for 81479 and the two other top Medicare codes due to their outsized impact.
On Medicaid the provider shows a more diversified top-code footprint: the precomputed top 3 Medicaid codes account for 63.0% of total Medicaid revenue, with leading contributions from 81420 ($34.8M, 26.8%), 81162 ($34.2M, 26.2%), and 81479 ($13M, 10.0%). This indicates Medicaid revenue is still concentrated in a few high-volume hereditary and prenatal genetic tests but is less dominated by a single code compared with Medicare, suggesting somewhat broader product penetration in Medicaid populations (e.g., prenatal cfDNA and BRCA testing).
Comparative scale between payers shows Medicaid receipts ($136.7M) exceed Medicare receipts ($71.4M), indicating this provider derives the majority of its public-payer revenue from Medicaid. That payer mix suggests INVITAE’s commercial strategy and operational capacity may be oriented toward longer-running, high-volume Medicaid contracts and programs (including prenatal and hereditary screening), and Medicaid reimbursement dynamics will materially affect total public revenue more than Medicare-specific shifts.
INVITAE ranks as a dominant national player on several trademark codes: it ranks #1 nationally for 81479 on Medicare (100th percentile; described as an extreme outlier) and also holds top national ranks for 81321 and 81404. For Medicaid in California, INVITAE is likewise a leading in‑state provider on many codes (for example 81162 ranks #1 in-state and 81420 ranks #5 but still in the 87th percentile). These rankings indicate the lab is a major competitor at the national level for select molecular pathology services and a top provider within California for multiple genetic tests.
The provider’s code-level percentiles include multiple labels indicating unusually high volume: Medicare 81479 is an "extreme outlier" nationally and several Medicaid codes are labeled "extreme outlier" or "notably above typical state volume" (e.g., Medicaid 81479 is a 98th‑percentile, extreme outlier in-state; 81162 and several tiered molecular codes are 100th‑percentile in-state). These descriptors signal that INVITAE’s testing volumes for specific genetic assays are far above typical peer volumes and that the organization is a statistical high-volume performer for those services in the referenced geographies.
Tenure data show the provider NPI was enumerated on 2012-05-11 (~14 years ago), indicating over a decade of operation under this NPI. That duration supports the observed scale as an established service provider rather than a new entrant, which may matter when assessing contracting history, operational maturity, and referral relationships.
Because Medicare revenue is nearly entirely concentrated in three codes (99.8% precomputed) while Medicaid’s top three account for a smaller share (63.0% precomputed), operational risk is asymmetric: Medicare exposure is concentrated in a single code (81479) and therefore more sensitive to code-specific reimbursement or coverage changes, whereas Medicaid revenue, while still concentrated, is spread across multiple high-volume prenatal, hereditary, and panel tests that may mitigate single-code risk. Payers and analysts should treat Medicare reimbursement shifts for 81479 as high-risk to Medicare revenue but consider Medicaid dynamics across several leading genetic tests when modeling overall public-payer revenue impact.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
8 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 40,810 | $1,670 | $68.1M |
| 81321 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the phosphatase and tensin homolog, or PTEN, gene. | 4,580 | $590 | $2.7M |
| 81404 | The lab analyst performs the technical lab tests to complete one of the specific genetic analyses listed in this Tier 2, Level 5 molecular pathology code. | 1,490 | $270 | $400K |
| 81405 | The lab analyst performs the technical lab tests to complete one of the specific genetic analyses listed in this Tier 2, Level 6 molecular pathology code. | 280 | $300 | $82K |
| 81406 | The lab analyst performs the technical lab test to complete one of the specific genetic analyses listed in this Tier 2, Level 7 molecular pathology code. | 110 | $280 | $29.6K |
| 81432 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least five genes relating to disorders associated with hereditary breast cancer… | 30 | $650 | $21.4K |
| 81435 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least five genes, which relate to hereditary colon cancer–related disorders.… | 20 | $550 | $11K |
| 81436 | – WARNING – Code Deleted 2024‑12‑31 | 20 | $570 | $10.9K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 8 CPT/HCPCS codes.
View: State1 / 2
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
118 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81420 | The lab analyst performs a genomic sequence analysis panel to evaluate circulating cell free fetal DNA in maternal blood for genetic sequences of at least the genes on chromosomes 13, 18, and 21,… | 155,480 | $220 | $34.8M |
| 81162 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the BRCA1, DNA repair–associated gene, also called BRCA1; and BRCA2, DNA repair–associated gene, also called… | 77,270 | $440 | $34.2M |
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 48,500 | $270 | $13M |
| 81220 | The lab analyst performs the technical lab test to detect the presence of changes in the gene for cystic fibrosis transmembrane conductance regulator, also known as CFTR. The test evaluates the CFTR… | 64,330 | $160 | $10M |
| 81408 | The lab analyst performs the technical lab test to complete one of the specific genetic analyses listed in this Tier 2, Level 9 molecular pathology code. | 38,760 | $220 | $8.6M |
| 81407 | The lab analyst performs the technical lab test to complete one of the specific genetic analyses listed in this Tier 2, Level 8 molecular pathology code. | 36,490 | $100 | $3.5M |
| 81419 | The lab analyst performs the technical lab test on a specimen such as blood to conduct a genomic sequence analysis panel. The test evaluates the genetic sequences of at least the 24 genes listed in… | 8,130 | $390 | $3.1M |
| 81229 | The lab analyst performs the technical lab test using comparative genomic hybridization (CGH) microarray, also referred to as chromosomal microarray (CMA) or molecular karyotype performed by… | 11,440 | $270 | $3.1M |
| 81406 | The lab analyst performs the technical lab test to complete one of the specific genetic analyses listed in this Tier 2, Level 7 molecular pathology code. | 50,540 | $40 | $2.2M |
| 81405 | The lab analyst performs the technical lab tests to complete one of the specific genetic analyses listed in this Tier 2, Level 6 molecular pathology code. | 50,180 | $40 | $2.2M |
Showing 1–10 of 118
How this provider's Medicaid billing volume and revenue compare to other California providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. California median
118 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81420 | The lab analyst performs a genomic sequence analysis panel to evaluate circulating cell free fetal DNA in maternal blood for genetic sequences of at least the genes on chromosomes 13, 18, and 21,… | 5 | 30 | 300 | $260 | $18M |
| 81408 | The lab analyst performs the technical lab test to complete one of the specific genetic analyses listed in this Tier 2, Level 9 molecular pathology code. | 2 | 10 | 380 | $230 | $10.8M |
| 81162 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the BRCA1, DNA repair–associated gene, also called BRCA1; and BRCA2, DNA repair–associated gene, also called… | 1 | 10 | 440 | $500 | $5.3M |
| 81443 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least 15 genes, such as the 20 gene examples listed in the code descriptor. The… | 5 | 10 | 3,040 | $290 | $4.7M |
| 81161 | The lab analyst performs the technical lab test to analyze specific changes involving deleted, or possibly repeated, nucleotide sequences in the dystrophin gene, also known as the DMD gene. | 3 | 10 | 3,090 | $40 | $3.5M |
| 81361 | The lab analyst performs the technical lab test to detect the presence of specific changes in the hemoglobin, subunit beta (HBB) gene specifically for common variants, such as HbS, HbC, HbE. | 4 | 10 | 900 | $30 | $1.9M |
| 81220 | The lab analyst performs the technical lab test to detect the presence of changes in the gene for cystic fibrosis transmembrane conductance regulator, also known as CFTR. The test evaluates the CFTR… | 5 | 110 | 190 | $140 | $1.6M |
| 81422 | The lab analyst performs a genomic sequence analysis panel to evaluate circulating cell–free fetal DNA in maternal blood for chromosomal microdeletion(s) associated with conditions such as DiGeorge… | 7 | 10 | 3,270 | $60 | $1.5M |
| 81419 | The lab analyst performs the technical lab test on a specimen such as blood to conduct a genomic sequence analysis panel. The test evaluates the genetic sequences of at least the 24 genes listed in… | 1 | 10 | 180 | $390 | $1.1M |
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 2 | 50 | 500 | $160 | $1.1M |
Showing 1–10 of 118
Other providers in the same ZIP code as Invitae Corporation, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| City & County Of San Francisco | CA | Community/Behavioral Health Agency | $0 | $1.3B |
| Irhythm Technologies, Inc. | CA | Physiological Laboratory | $94M | $19.2M |
| Healthright 360 | CA | Federally Qualified Health Center (FQHC) | $0 | $40.9M |
| Medi-lynx Cardiac Monitoring, LLC | CA | Physiological Laboratory | $3.6M | $209.7K |
| David Kornguth | CA | Radiation Oncology Physician | $2.6M | $0 |
| Rhythmscience Inc. | CA | Physiological Laboratory | $63.4K | $650 |
| Jadine Cehand | CA | Registered Nurse | $12.2K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.